With over 15 years of experience in immunology and oncology, Dr. Jane Smith leads the research and development of TCR-T cell therapies at OncoVanta Therapeutics. She is dedicated to advancing cancer treatments through innovative research and collaboration. Dr. Smith has published numerous articles in prominent journals and is passionate about translating scientific discoveries into real-world solutions for patients. Her expertise in mutant TP53 cancers positions her as a pioneer in the field, driving the mission to transform cancer care. Her leadership fosters a culture of innovation and excellence.